本文内容仅供医疗卫生等专业人士参考。
方法 | 单中心回顾性研究,三个队列:艾曲泊帕、rhTPO或未接受治疗的淋巴瘤CIT患者
结果 | 艾曲泊帕——有效安全升板,降低出血风险,减少血小板输注
艾曲泊帕——显著提升血小板计数
表1 三组的血小板计数及比较
注:数据为平均值±SD。
a P值比较了三组之间的血小板计数。
b 定义为治疗开始后(或对照组患者入组后)观察到的最低血小板计数。
c 第0天和第3天之间血小板计数比较的P值。
d 第0天和第5天之间血小板计数比较的P值。
e 第0天和第7天之间血小板计数比较的P值。
f 第0天和第10天之间血小板计数比较的P值。
图1 三组治疗期间的平均血小板计数
艾曲泊帕——降低2-3级及总体出血率
图1 三组出血患者比例(参照WHO分级)
艾曲泊帕——降低血小板输注患者比例
艾曲泊帕——耐受性良好
结论 | 艾曲泊帕可作为淋巴瘤CIT治疗新方法
专家点评
潘学谊 教授
广东药科大学附属第一医院大内科主任、血液内科主任
广东省抗癌协会淋巴瘤专业委员会副主委
广州市医学会血液学分会副主委
广东省健康管理学会血液病学分会副主委
广东省药学会血液学分会副主委
广东省精准医学应用学会淋巴瘤分会副主委
[1] 中国临床肿瘤学会(CSCO)抗淋巴瘤联盟, 中国临床肿瘤学会(CSCO)抗白血病联盟. 淋巴瘤化疗所致血小板减少症防治中国专家共识[J]. 白血病.淋巴瘤, 2020(2):65-72.
[2] https://db.yaozh.com/instruct/19367.html.
[3] Winer ES, Safran H, Karaszewska B, et al. Eltrombopag for Thrombocytopenia in Patients With Advanced Solid Tumors Receiving Gemcitabine-Based Chemotherapy: A Randomized, Placebo-Controlled Phase 2 Study[J]. Int J Hematol, 2017, 106:765–76.
[4] Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, et al. A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Eltrombopag in Patients Receiving Carboplatin/Paclitaxel for Advanced Solid Tumors[J]. Curr Med Res Opin, 2010, 26:2339–46.
[5] Zhu Q, Yang S, Zeng W, et al. A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia[J]. Frontiers in Oncology, 2021,11.
[6] Zhang X, Chuai Y, Nie W, et al. Thrombopoietin Receptor Agonists for Prevention and Treatment of Chemotherapy-Induced Thrombocytopenia in Patients With Solid Tumors[J]. Cochrane Database Syst Rev, 2017, 11:CD12035.
[7] Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia[J]. J Clin Oncol, 2001,19(4):1137-1146.
[8] Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapyinduced thrombocytopenia among patients with lymphoma or solid tumors [J]. Cancer, 2003, 97(6):1541-1550.
[89] Winer ES, Safran H, Karaszewska B, et al. Eltrombopag With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors: A Randomized Phase I Study[J]. Cancer Med, 2015, 4:16–26.
[10] Platzbecker U, Wong RS, Verma A,et al. Safety and Tolerability of Eltrombopag Versus Placebo for Treatment of Thrombocytopenia in Patients With Advanced Myelodysplastic Syndromes or Acute Myeloid Leukaemia: A Multicentre, Randomised, Placebo-Controlled, Double-Blind, Phase 1/2 Trial[J]. Lancet Haematol, 2015, 2:e417– 426.
[11] https://clinicaltrials.gov.
此产品或适应症尚未在中国获得批准,相关内容仅供学术交流。